Pub Date : 2025-11-03eCollection Date: 2025-01-01DOI: 10.1177/20480040251393769
Lith Nasif, Carrie Herbert, Surendranath R Veeram Reddy, Thomas M Zellers, Stephan Wu, Abhay Divekar, Michael Wu, Song Zhang, Yousef Arar
Objectives: The aim of this study is to evaluate the impact of anticoagulation strategy, stent type, and pulmonary artery (PA) jailing on unplanned reintervention rates and PA growth in neonates undergoing patent ductus arteriosus (PDA) stenting. Specifically, we compared aspirin monotherapy versus aspirin plus Enoxaparin, bare metal versus drug-eluting stents, and jailed versus non-jailed PAs.
Methods: A retrospective chart review was conducted on neonates who underwent PDA stenting between 2014 and 2024. Patients were categorized by stent type, anticoagulation regimen, and PA jailing status. Unplanned reintervention rates were assessed using chi-square analysis and logistic regression. PA growth was evaluated using catheterization, MRI, and CT imaging. Statistical analyses of PA growth included t-tests and regression models.
Results: Among 116 neonates analyzed, aspirin monotherapy was associated with a significantly lower unplanned reintervention rate compared to combination therapy with Enoxaparin (p = 0.0447). Stent type did not significantly impact reintervention rates. Additionally, intrapatient jailed PAs exhibited significantly reduced distal growth compared to non-jailed PAs (p = 0.0070).
Conclusions: For neonatal PDA stenting, aspirin monotherapy may be as effective as aspirin plus Enoxaparin for post-stenting anticoagulation, and drug eluting stents may not have a significant benefit over bare metal stents. Furthermore, PA jailing may negatively impact distal vessel growth, highlighting the need for refined stent placement techniques, although further prospective studies are needed to optimize procedural strategies and long-term outcomes in this high-risk neonatal population.
{"title":"Neonatal PDA stent considerations: Retrospective review of anticoagulation, stent type, and PA jailing.","authors":"Lith Nasif, Carrie Herbert, Surendranath R Veeram Reddy, Thomas M Zellers, Stephan Wu, Abhay Divekar, Michael Wu, Song Zhang, Yousef Arar","doi":"10.1177/20480040251393769","DOIUrl":"10.1177/20480040251393769","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study is to evaluate the impact of anticoagulation strategy, stent type, and pulmonary artery (PA) jailing on unplanned reintervention rates and PA growth in neonates undergoing patent ductus arteriosus (PDA) stenting. Specifically, we compared aspirin monotherapy versus aspirin plus Enoxaparin, bare metal versus drug-eluting stents, and jailed versus non-jailed PAs.</p><p><strong>Methods: </strong>A retrospective chart review was conducted on neonates who underwent PDA stenting between 2014 and 2024. Patients were categorized by stent type, anticoagulation regimen, and PA jailing status. Unplanned reintervention rates were assessed using chi-square analysis and logistic regression. PA growth was evaluated using catheterization, MRI, and CT imaging. Statistical analyses of PA growth included t-tests and regression models.</p><p><strong>Results: </strong>Among 116 neonates analyzed, aspirin monotherapy was associated with a significantly lower unplanned reintervention rate compared to combination therapy with Enoxaparin (<i>p</i> = 0.0447). Stent type did not significantly impact reintervention rates. Additionally, intrapatient jailed PAs exhibited significantly reduced distal growth compared to non-jailed PAs (<i>p</i> = 0.0070).</p><p><strong>Conclusions: </strong>For neonatal PDA stenting, aspirin monotherapy may be as effective as aspirin plus Enoxaparin for post-stenting anticoagulation, and drug eluting stents may not have a significant benefit over bare metal stents. Furthermore, PA jailing may negatively impact distal vessel growth, highlighting the need for refined stent placement techniques, although further prospective studies are needed to optimize procedural strategies and long-term outcomes in this high-risk neonatal population.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251393769"},"PeriodicalIF":1.5,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12583843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-03eCollection Date: 2025-01-01DOI: 10.1177/20480040251393767
Lin Chen, Fei Wang, Hui Zhang, Sheng Qin, Ming Sui, Tomoaki Ishigami
Background: Acute myocardial infarction (AMI) remains a major cause of global mortality, with post-infarction cardiovascular events significantly contributing to poor outcomes. Emerging evidence suggests that gut microbiome dysbiosis may influence cardiovascular risk through increased intestinal permeability and systemic inflammation. Although lactulose-a prebiotic known to modulate gut microbiota-has shown beneficial effects in experimental models, its impact on major adverse cardiovascular events (MACEs) after AMI remains unclear.
Methods: In this single-center retrospective cohort study, we analyzed 165 AMI patients hospitalized between 2016 and 2019. Participants were stratified by lactulose use during hospitalization. The primary outcome was in-hospital MACEs. Multivariable logistic regression was used. Secondary outcomes included pneumonia incidence and length of hospital stay.
Results: After adjustment for confounders, lactulose use was independently associated with a reduced risk of MACEs (adjusted odds ratio (OR) 0.40, 95% confidence interval (CI) 0.16-0.95; p = 0.038). The overall incidence of MACEs was 18.2% in the lactulose group versus 30.0% in controls, though this difference was not statistically significant in unadjusted analysis (χ² = 2.41, p = 0.12), likely reflecting limited statistical power. No significant associations were observed for pneumonia (OR = 0.17, p = 0.09) or hospital stay duration (p = 0.60).
Conclusions: In this retrospective analysis, lactulose supplementation was associated with reduced in-hospital cardiovascular events following AMI. However, these preliminary findings require validation in larger prospective studies to establish causality and elucidate underlying gut-mediated mechanisms. If confirmed, lactulose may represent a simple and accessible adjunct therapy in post-infarction care.
{"title":"Lactulose for prevention of cardiovascular events after myocardial infarction: A retrospective cohort study.","authors":"Lin Chen, Fei Wang, Hui Zhang, Sheng Qin, Ming Sui, Tomoaki Ishigami","doi":"10.1177/20480040251393767","DOIUrl":"10.1177/20480040251393767","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) remains a major cause of global mortality, with post-infarction cardiovascular events significantly contributing to poor outcomes. Emerging evidence suggests that gut microbiome dysbiosis may influence cardiovascular risk through increased intestinal permeability and systemic inflammation. Although lactulose-a prebiotic known to modulate gut microbiota-has shown beneficial effects in experimental models, its impact on major adverse cardiovascular events (MACEs) after AMI remains unclear.</p><p><strong>Methods: </strong>In this single-center retrospective cohort study, we analyzed 165 AMI patients hospitalized between 2016 and 2019. Participants were stratified by lactulose use during hospitalization. The primary outcome was in-hospital MACEs. Multivariable logistic regression was used. Secondary outcomes included pneumonia incidence and length of hospital stay.</p><p><strong>Results: </strong>After adjustment for confounders, lactulose use was independently associated with a reduced risk of MACEs (adjusted odds ratio (OR) 0.40, 95% confidence interval (CI) 0.16-0.95; p = 0.038). The overall incidence of MACEs was 18.2% in the lactulose group versus 30.0% in controls, though this difference was not statistically significant in unadjusted analysis (χ² = 2.41, p = 0.12), likely reflecting limited statistical power. No significant associations were observed for pneumonia (OR = 0.17, p = 0.09) or hospital stay duration (p = 0.60).</p><p><strong>Conclusions: </strong>In this retrospective analysis, lactulose supplementation was associated with reduced in-hospital cardiovascular events following AMI. However, these preliminary findings require validation in larger prospective studies to establish causality and elucidate underlying gut-mediated mechanisms. If confirmed, lactulose may represent a simple and accessible adjunct therapy in post-infarction care.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251393767"},"PeriodicalIF":1.5,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12583842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: A variety of studies have reported the associations between histone deacetylases (HDACs) genes and cardio-cerebrovascular diseases. The identification of variants in the HDACs genes and the determination of risk alleles could open novel therapeutic avenues for these diseases. This article summarized variants in HDACs genes and different sub-types of cardio-cerebrovascular diseases. Methods: A comprehensive literature search was conducted across PubMed, Web of Science and Scopus databases to identify studies published prior to 27 June 2025. We registered this protocol in the PROSPERO database (CRD420251010100). The Venice Criteria were applied to assess the statistically significant associations identified by meta-analyses. The single-nucleotide polymorphisms were mapped to their corresponding genes, and functional annotation was conducted using the Encyclopedia of DNA Elements tool, HaploReg and the UCSC Genome browser. Results: We finally included 34 published studies and 160 datasets to assess the associations between variants in HDAC genes and cardio-cerebrovascular diseases. Rs2107595 in HDAC 9 was the variant found to be associated with four sub-types identified by genome-wide association study or meta-analyses. Rs11984041 was related to ischemic stroke. Rs10230207 and rs2192476 were associated with intracranial aneurysm. Conclusions:HDACs genes were associated with multiple cardio-cerebrovascular diseases. However, ethnic disparities were observed in their effects. Therefore, ethnicity-targeted treatments, including specific HDAC inhibitors, should be developed in the future.
背景:多种研究报道了组蛋白去乙酰化酶(hdac)基因与心脑血管疾病之间的关联。hdac基因变异的鉴定和风险等位基因的确定可能为这些疾病开辟新的治疗途径。本文综述了HDACs基因变异与心脑血管疾病不同亚型的关系。方法:对PubMed、Web of Science和Scopus数据库进行全面的文献检索,以确定2025年6月27日之前发表的研究。我们在PROSPERO数据库(CRD420251010100)中注册了该协议。应用威尼斯标准评估meta分析确定的统计学显著关联。将单核苷酸多态性定位到相应的基因,并使用百科全书DNA元件工具、HaploReg和UCSC基因组浏览器进行功能注释。结果:我们最终纳入了34项已发表的研究和160个数据集,以评估HDAC基因变异与心脑血管疾病之间的关系。HDAC 9中的Rs2107595是通过全基因组关联研究或荟萃分析发现的与四种亚型相关的变异。Rs11984041与缺血性脑卒中相关。Rs10230207和rs2192476与颅内动脉瘤相关。结论:hdac基因与多种心脑血管疾病相关。然而,在其影响中观察到种族差异。因此,未来应该开发针对种族的治疗方法,包括特异性HDAC抑制剂。
{"title":"Cumulative evidence for associations between variants in the histone deacetylases genes and cardio-cerebrovascular diseases: A systematic review and meta-analysis.","authors":"Dongqing Gu, Rui Li, Kaiwen Deng, Weizhong Chen, Bin Han, Ziqian Zeng","doi":"10.1177/20480040251391397","DOIUrl":"10.1177/20480040251391397","url":null,"abstract":"<p><p><b>Background:</b> A variety of studies have reported the associations between <i>histone deacetylases</i> (<i>HDACs</i>) genes and cardio-cerebrovascular diseases. The identification of variants in the <i>HDACs</i> genes and the determination of risk alleles could open novel therapeutic avenues for these diseases. This article summarized variants in <i>HDACs</i> genes and different sub-types of cardio-cerebrovascular diseases. <b>Methods:</b> A comprehensive literature search was conducted across PubMed, Web of Science and Scopus databases to identify studies published prior to 27 June 2025. We registered this protocol in the PROSPERO database (CRD420251010100). The Venice Criteria were applied to assess the statistically significant associations identified by meta-analyses. The single-nucleotide polymorphisms were mapped to their corresponding genes, and functional annotation was conducted using the Encyclopedia of DNA Elements tool, HaploReg and the UCSC Genome browser. <b>Results:</b> We finally included 34 published studies and 160 datasets to assess the associations between variants in <i>HDAC</i> genes and cardio-cerebrovascular diseases. Rs2107595 in <i>HDAC</i> 9 was the variant found to be associated with four sub-types identified by genome-wide association study or meta-analyses. Rs11984041 was related to ischemic stroke. Rs10230207 and rs2192476 were associated with intracranial aneurysm. <b>Conclusions:</b> <i>HDACs</i> genes were associated with multiple cardio-cerebrovascular diseases. However, ethnic disparities were observed in their effects. Therefore, ethnicity-targeted treatments, including specific HDAC inhibitors, should be developed in the future.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251391397"},"PeriodicalIF":1.5,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12576083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145432406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-21eCollection Date: 2025-01-01DOI: 10.1177/20480040251385762
Jinghong Zhang, Ziqian Zhao, Xiaoyu Liu
Objective: This study aimed to investigate the association between smoking and plasma levels of sCD40L, sP-selectin, and sICAM-1 in patients with coronary heart disease (CHD), and to evaluate their correlations with smoking intensity and coronary anatomical complexity assessed by the SYNTAX score.
Methods: We analyzed data from 244 patients with CHD undergoing percutaneous coronary intervention, categorized into smokers (n = 150) and nonsmokers (n = 94). Smoking intensity was quantified using the smoking index (SI). Plasma biomarker levels were measured via ELISA. SYNTAX scores I and II were assessed by two experienced interventional cardiologists to evaluate coronary lesion complexity. Group comparisons, Spearman's correlation adjusted with the Benjamini-Hochberg method, tests for interaction (Gender × Smoking Status), and multivariate regression models were employed.
Results: Smokers exhibited significantly higher sICAM-1 levels than nonsmokers (662.6 vs. 548.6 ng/ml, P = 0.007). sICAM-1 was an independent risk factor for CHD in smokers (OR = 1.001, 95% CI: 1.00003-1.033, P = 0.043). Strong correlations were observed among all three biomarkers (all P < 0.001). Subgroup analyses showed significant correlations between SI and all three biomarkers, and both SI and sP-selectin correlated positively with SYNTAX scores I and II (all P < 0.01). Formal interaction analysis indicated no significant effect modification by gender on the observed associations (all P >> 0.05).
Conclusion: Elevated levels of sICAM-1, sCD40L, and sP-selectin are interrelated and associated with smoking intensity and coronary anatomical complexity, highlighting their role as key inflammatory mediators in smoking-related CHD.
{"title":"The association between plasma levels of sCD40L, sP-selectin, and sICAM-1 and smoking-induced coronary heart disease: A cross-sectional study.","authors":"Jinghong Zhang, Ziqian Zhao, Xiaoyu Liu","doi":"10.1177/20480040251385762","DOIUrl":"10.1177/20480040251385762","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the association between smoking and plasma levels of sCD40L, sP-selectin, and sICAM-1 in patients with coronary heart disease (CHD), and to evaluate their correlations with smoking intensity and coronary anatomical complexity assessed by the SYNTAX score.</p><p><strong>Methods: </strong>We analyzed data from 244 patients with CHD undergoing percutaneous coronary intervention, categorized into smokers (n = 150) and nonsmokers (n = 94). Smoking intensity was quantified using the smoking index (SI). Plasma biomarker levels were measured via ELISA. SYNTAX scores I and II were assessed by two experienced interventional cardiologists to evaluate coronary lesion complexity. Group comparisons, Spearman's correlation adjusted with the Benjamini-Hochberg method, tests for interaction (Gender × Smoking Status), and multivariate regression models were employed.</p><p><strong>Results: </strong>Smokers exhibited significantly higher sICAM-1 levels than nonsmokers (662.6 vs. 548.6 ng/ml, <i>P</i> = 0.007). sICAM-1 was an independent risk factor for CHD in smokers (OR = 1.001, 95% CI: 1.00003-1.033, <i>P</i> = 0.043). Strong correlations were observed among all three biomarkers (all <i>P</i> < 0.001). Subgroup analyses showed significant correlations between SI and all three biomarkers, and both SI and sP-selectin correlated positively with SYNTAX scores I and II (all <i>P</i> < 0.01). Formal interaction analysis indicated no significant effect modification by gender on the observed associations (all <i>P</i> >> 0.05).</p><p><strong>Conclusion: </strong>Elevated levels of sICAM-1, sCD40L, and sP-selectin are interrelated and associated with smoking intensity and coronary anatomical complexity, highlighting their role as key inflammatory mediators in smoking-related CHD.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251385762"},"PeriodicalIF":1.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12552778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-29eCollection Date: 2025-01-01DOI: 10.1177/20480040251380392
Zainab Haider Ejaz, Muhammad Fahad Maya, Fizzah Kazim, Zahira Amir Ali, Naureen Akber Ali, Adeel Khoja
Background: Climate change and increasing environmental pollution are emerging as significant threats to global health, notably through their impact on cardiovascular diseases (CVD). The World Health Organization (WHO) attributes millions of premature deaths annually to air pollution and extreme temperatures. Despite extensive research on air pollution and temperature extremes separately, their combined effects on cardiovascular health remain inadequately explored.
Methods: We plan to conduct a systematic review and meta-analysis to assess the impact of climate change, including extremes of temperature and air pollution, on CVD. We will search PubMed, CINAHL, SCOPUS, ClinicalTrials.gov, and additional databases for studies published between August 12, 2019, and August 11, 2024. The review will include observational and quasi-experimental (pre and post-test) studies. Data extraction and quality assessment will be performed using EndNote, Rayyan.ai, and the National Heart, Lung, and Blood Institute (NHLBI) quality appraisal tool. The statistical analysis will be conducted using RevMan 5.4, with risk ratios, mean differences, and heterogeneity evaluated.
Discussion: This review aims to synthesize evidence on how ambient air pollutants (PM2.5, CO, O3) and extreme temperatures contribute to cardiovascular morbidity and mortality. It will highlight the synergistic effects of air pollution and temperature extremes, with a particular focus on low- and middle-income countries where the burden is most pronounced.
Conclusion: By integrating the impacts of both climate change and air pollution on cardiovascular health, this review will provide comprehensive insights into the global health burden of CVD. The findings will inform public health strategies and interventions to mitigate the adverse effects of environmental factors on cardiovascular health.
{"title":"Impact of climate change and air pollution on cardiovascular disease: A systematic review and meta-analysis protocol.","authors":"Zainab Haider Ejaz, Muhammad Fahad Maya, Fizzah Kazim, Zahira Amir Ali, Naureen Akber Ali, Adeel Khoja","doi":"10.1177/20480040251380392","DOIUrl":"10.1177/20480040251380392","url":null,"abstract":"<p><strong>Background: </strong>Climate change and increasing environmental pollution are emerging as significant threats to global health, notably through their impact on cardiovascular diseases (CVD). The World Health Organization (WHO) attributes millions of premature deaths annually to air pollution and extreme temperatures. Despite extensive research on air pollution and temperature extremes separately, their combined effects on cardiovascular health remain inadequately explored.</p><p><strong>Methods: </strong>We plan to conduct a systematic review and meta-analysis to assess the impact of climate change, including extremes of temperature and air pollution, on CVD. We will search PubMed, CINAHL, SCOPUS, ClinicalTrials.gov, and additional databases for studies published between August 12, 2019, and August 11, 2024. The review will include observational and quasi-experimental (pre and post-test) studies. Data extraction and quality assessment will be performed using EndNote, Rayyan.ai, and the National Heart, Lung, and Blood Institute (NHLBI) quality appraisal tool. The statistical analysis will be conducted using RevMan 5.4, with risk ratios, mean differences, and heterogeneity evaluated.</p><p><strong>Discussion: </strong>This review aims to synthesize evidence on how ambient air pollutants (PM<sub>2.5</sub>, CO, O<sub>3</sub>) and extreme temperatures contribute to cardiovascular morbidity and mortality. It will highlight the synergistic effects of air pollution and temperature extremes, with a particular focus on low- and middle-income countries where the burden is most pronounced.</p><p><strong>Conclusion: </strong>By integrating the impacts of both climate change and air pollution on cardiovascular health, this review will provide comprehensive insights into the global health burden of CVD. The findings will inform public health strategies and interventions to mitigate the adverse effects of environmental factors on cardiovascular health.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251380392"},"PeriodicalIF":1.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-03eCollection Date: 2025-01-01DOI: 10.1177/20480040251371770
Rubina Mulchandani, Ashish Kumar Kakkar, Sheetal Gandotra, H S Isser, Rajinder K Dhamija, Tanica Lyngdoh
Background: Statins are the most widely prescribed drugs for dyslipidemia and CAD. But evidence on their cognitive effects is conflicting. A unique genetic makeup and variable lipid patterns make South Asians more susceptible to statin adverse effects. But literature on statin safety in this group is scarce. We aimed to assess the cognitive status of adult Indian statin users over two years and explore factors associated with it.
Methods: A prospective cohort was established for cognitive profiling of adult statin users, visiting the out-patient cardiology department of a tertiary care center in North India. The Montreal Cognitive Assessment Scale measured cognitive function. Analysis was conducted using mixed-effects linear regression modelling to account for repeated measurements.
Results: 273 participants were enrolled. The mean cognitive score was 15. Age and education were significant predictors of cognition (P-value .005 and <.001 respectively). Participants over 60 scored had significantly lower scores and those who had completed secondary school and above scored significantly higher scores. No significant associations were observed between cognitive score and other covariates- sex, follow-up period, statin type and duration of use.
Conclusion: The statins-cognition relationship is controversial. This study demonstrated statistically significant relationships of cognition with age and education and showed no change in cognition over 2 years. The findings provide hypotheses for more in-depth assessments. Statins remain the most effective lipid-lowering treatment. However, further research is warranted for a more holistic understanding of the issue & optimizing their risk-benefit ratio.
{"title":"Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India.","authors":"Rubina Mulchandani, Ashish Kumar Kakkar, Sheetal Gandotra, H S Isser, Rajinder K Dhamija, Tanica Lyngdoh","doi":"10.1177/20480040251371770","DOIUrl":"10.1177/20480040251371770","url":null,"abstract":"<p><strong>Background: </strong>Statins are the most widely prescribed drugs for dyslipidemia and CAD. But evidence on their cognitive effects is conflicting. A unique genetic makeup and variable lipid patterns make South Asians more susceptible to statin adverse effects. But literature on statin safety in this group is scarce. We aimed to assess the cognitive status of adult Indian statin users over two years and explore factors associated with it.</p><p><strong>Methods: </strong>A prospective cohort was established for cognitive profiling of adult statin users, visiting the out-patient cardiology department of a tertiary care center in North India. The Montreal Cognitive Assessment Scale measured cognitive function. Analysis was conducted using mixed-effects linear regression modelling to account for repeated measurements.</p><p><strong>Results: </strong>273 participants were enrolled. The mean cognitive score was 15. Age and education were significant predictors of cognition (<i>P</i>-value .005 and <.001 respectively). Participants over 60 scored had significantly lower scores and those who had completed secondary school and above scored significantly higher scores. No significant associations were observed between cognitive score and other covariates- sex, follow-up period, statin type and duration of use.</p><p><strong>Conclusion: </strong>The statins-cognition relationship is controversial. This study demonstrated statistically significant relationships of cognition with age and education and showed no change in cognition over 2 years. The findings provide hypotheses for more in-depth assessments. Statins remain the most effective lipid-lowering treatment. However, further research is warranted for a more holistic understanding of the issue & optimizing their risk-benefit ratio.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251371770"},"PeriodicalIF":1.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aimed to investigate the relationship between the stress hyperglycaemia ratio and haemorrhagic transformation after intravenous thrombolysis in acute ischaemic stroke patients.
Methods: We analysed data in Shanghai General Hospital from 2019 to 2022 on 161 men and 68 women with valid data on fasting blood glucose, glycated haemoglobin, and cranial computed tomography using multivariable regression models to examine the relationship between hyperglycaemia ratio and haemorrhagic transformation.
Results: All 229 patients in this study were included, with 161 males (70.3%) and a mean age of 69.0 (SD = 11.3). According to the median hyperglycaemia ratio (0.87), all patients were divided into two groups (M1 ≤ 0.87). Patients in the M2 group tended to have a higher fasting blood glucose, body mass index, glycated albumin, and apolipoprotein E, while the door-to-needle time in M2 was longer than in M1 (all p values < 0.05). The fasting blood glucose, hyperglycaemia ratio, urea nitrogen, glycated albumin, D-dimer, and the score of NIHSS in the haemorrhagic transformation group were higher than in the non-haemorrhagic transformation group, but the haemoglobin was lower (all p values < 0.05). In the overall population, the hyperglycaemia ratio was associated with haemorrhagic transformation after intravenous thrombolysis before and after full adjustment for age, sex, body mass index, hyperglycaemia ratio, glycated albumin, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein E, door-to-needle time and the score of National Institute of Health Stroke Scale [OR = 3.34, 95% CI: 1.27-7.76].
Conclusions: This result implied that the hyperglycaemia ratio is significantly associated with haemorrhagic transformation after intravenous thrombolysis in stroke patients. The stress hyperglycaemia ratio should be borne in mind after intravenous thrombolysis regarding the incidence of haemorrhagic transformation.
{"title":"Effect of stress hyperglycaemia on the occurrence of haemorrhagic transformation after thrombolysis in patients with acute ischaemic stroke.","authors":"Yu Wang, Xi-Xi Wang, Yu-Lei Zhang, Jia-Ming Song, Kai-Ze Zhou, Jun-Fang Zhang, Guo-Dong Wang, Xin-Jun Li, Ya Feng, Yun-Cheng Wu","doi":"10.1177/20480040251365373","DOIUrl":"10.1177/20480040251365373","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the relationship between the stress hyperglycaemia ratio and haemorrhagic transformation after intravenous thrombolysis in acute ischaemic stroke patients.</p><p><strong>Methods: </strong>We analysed data in Shanghai General Hospital from 2019 to 2022 on 161 men and 68 women with valid data on fasting blood glucose, glycated haemoglobin, and cranial computed tomography using multivariable regression models to examine the relationship between hyperglycaemia ratio and haemorrhagic transformation.</p><p><strong>Results: </strong>All 229 patients in this study were included, with 161 males (70.3%) and a mean age of 69.0 (SD = 11.3). According to the median hyperglycaemia ratio (0.87), all patients were divided into two groups (M1 ≤ 0.87). Patients in the M2 group tended to have a higher fasting blood glucose, body mass index, glycated albumin, and apolipoprotein E, while the door-to-needle time in M2 was longer than in M1 (all <i>p</i> values < 0.05). The fasting blood glucose, hyperglycaemia ratio, urea nitrogen, glycated albumin, D-dimer, and the score of NIHSS in the haemorrhagic transformation group were higher than in the non-haemorrhagic transformation group, but the haemoglobin was lower (all <i>p</i> values < 0.05). In the overall population, the hyperglycaemia ratio was associated with haemorrhagic transformation after intravenous thrombolysis before and after full adjustment for age, sex, body mass index, hyperglycaemia ratio, glycated albumin, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein E, door-to-needle time and the score of National Institute of Health Stroke Scale [OR = 3.34, 95% CI: 1.27-7.76].</p><p><strong>Conclusions: </strong>This result implied that the hyperglycaemia ratio is significantly associated with haemorrhagic transformation after intravenous thrombolysis in stroke patients. The stress hyperglycaemia ratio should be borne in mind after intravenous thrombolysis regarding the incidence of haemorrhagic transformation.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251365373"},"PeriodicalIF":1.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac tamponade is a rare, life-threatening condition caused by accumulation of pericardial fluid, leading to rapid changes in hemodynamic status. Common causes include cancer, chest trauma, pericarditis, autoimmune diseases, and infectious agents such as viruses, bacteria, and fungi. Patients typically present with symptoms of weakness, chest pain, and shortness of breath. We present the case of a young female who presented with obstructive shock and echocardiographic evidence of tamponade. She was worked up and found to have cardiogenic shock likely secondary to systemic lupus erythematosus and fulminant myopericarditis. Prompt intervention with pericardiocentesis of 250 mL of exudative fluid led to significant improvement in left ventricle function and hemodynamic stability. The case highlights the importance for early recognition and a broad differential diagnosis-including autoimmune causes-when evaluating potential tamponade.
{"title":"Autoimmune fulminant myopericarditis presenting as cardiac tamponade-A rare occurrence in a patient with systemic lupus erythematosus.","authors":"Amanpreet Singh Wasir, Anuj Darak, Jagroop Doad, Prashant Bharadwaj, Ravi Kalra","doi":"10.1177/20480040251368556","DOIUrl":"10.1177/20480040251368556","url":null,"abstract":"<p><p>Cardiac tamponade is a rare, life-threatening condition caused by accumulation of pericardial fluid, leading to rapid changes in hemodynamic status. Common causes include cancer, chest trauma, pericarditis, autoimmune diseases, and infectious agents such as viruses, bacteria, and fungi. Patients typically present with symptoms of weakness, chest pain, and shortness of breath. We present the case of a young female who presented with obstructive shock and echocardiographic evidence of tamponade. She was worked up and found to have cardiogenic shock likely secondary to systemic lupus erythematosus and fulminant myopericarditis. Prompt intervention with pericardiocentesis of 250 mL of exudative fluid led to significant improvement in left ventricle function and hemodynamic stability. The case highlights the importance for early recognition and a broad differential diagnosis-including autoimmune causes-when evaluating potential tamponade.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251368556"},"PeriodicalIF":1.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-06eCollection Date: 2025-01-01DOI: 10.1177/20480040251365987
Bronagh Kelly, Niki Walker
Pregnancy is an exciting time, with great anticipation of the future for the woman and her baby. However, for women with mechanical heart valves (MHVs) pregnancy is a challenging undertaking fraught with risk to them and their baby. This article considers the issues for the woman, highlighting pre-surgical opportunities, pre-pregnancy counselling, the issues to consider with fertility treatment, the options during pregnancy for anti-coagulation management and the recognition and management of complications. This update stresses the complex challenges in the management of women with MHV during pregnancy and the need for specialist multi-disciplinary team involvement.
{"title":"Mechanical heart valves and pregnancy.","authors":"Bronagh Kelly, Niki Walker","doi":"10.1177/20480040251365987","DOIUrl":"10.1177/20480040251365987","url":null,"abstract":"<p><p>Pregnancy is an exciting time, with great anticipation of the future for the woman and her baby. However, for women with mechanical heart valves (MHVs) pregnancy is a challenging undertaking fraught with risk to them and their baby. This article considers the issues for the woman, highlighting pre-surgical opportunities, pre-pregnancy counselling, the issues to consider with fertility treatment, the options during pregnancy for anti-coagulation management and the recognition and management of complications. This update stresses the complex challenges in the management of women with MHV during pregnancy and the need for specialist multi-disciplinary team involvement.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251365987"},"PeriodicalIF":1.5,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144800433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: To examine whether the factors determining discharge destination after acute-phase treatment for stroke differ based on recurrence risk levels.
Main outcome measures: Patients were stratified using the Stroke Prognosis Instrument II (SPI-II) and evaluated through forced-entry multiple logistic regression analysis. Among the independent variables, the primary outcome measure was the modified Rankin Scale (mRS) at discharge. Covariates included age, sex, and histories of diabetes, cerebral infarction, cerebral hemorrhage, coronary artery disease, hypertension, and congestive heart failure. The dependent variable grouped participants into those discharged home and those discharged to a medical facility.
Results: Among the 1219 included participants, 914 were classified into the home care group and 305 into the medical facility care group. SPI-II-based stratification revealed that 78.665% of the home care group had a moderate or higher risk of stroke recurrence. Multiple logistic regression analysis demonstrated that mRS at discharge was a significant factor across all stratified models, while age was a significant factor only within the moderate-risk group.
Conclusions: Discharge decisions after acute-phase treatment were primarily influenced by short-term functional independence, as reflected by mRS, rather than recurrence risk levels. Thus, a substantial proportion of stroke survivors with a high recurrence risk transitioned to home care. These findings highlight the need to revise current medical and social welfare services and to develop targeted strategies for stroke recurrence prevention, based on a more detailed understanding of the living environments of stroke survivors.
{"title":"A high-risk population for stroke recurrence exists among home-based stroke survivors discharged from an acute care hospital: A retrospective analysis.","authors":"Kyosuke Fukuda, Hikaru Izumiya, Soichi Kondo, Kosuke Okada, Kyoko Hirata, Chisaki Onoda, Takashi Amari, Yuta Sakamoto, Takuya Miyahara, Yuki Hamano","doi":"10.1177/20480040251362577","DOIUrl":"10.1177/20480040251362577","url":null,"abstract":"<p><strong>Objectives: </strong>To examine whether the factors determining discharge destination after acute-phase treatment for stroke differ based on recurrence risk levels.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Setting: </strong>General acute care hospital.</p><p><strong>Participants: </strong>Acute ischemic stroke survivors (<i>n</i> = 1219).</p><p><strong>Main outcome measures: </strong>Patients were stratified using the Stroke Prognosis Instrument II (SPI-II) and evaluated through forced-entry multiple logistic regression analysis. Among the independent variables, the primary outcome measure was the modified Rankin Scale (mRS) at discharge. Covariates included age, sex, and histories of diabetes, cerebral infarction, cerebral hemorrhage, coronary artery disease, hypertension, and congestive heart failure. The dependent variable grouped participants into those discharged home and those discharged to a medical facility.</p><p><strong>Results: </strong>Among the 1219 included participants, 914 were classified into the home care group and 305 into the medical facility care group. SPI-II-based stratification revealed that 78.665% of the home care group had a moderate or higher risk of stroke recurrence. Multiple logistic regression analysis demonstrated that mRS at discharge was a significant factor across all stratified models, while age was a significant factor only within the moderate-risk group.</p><p><strong>Conclusions: </strong>Discharge decisions after acute-phase treatment were primarily influenced by short-term functional independence, as reflected by mRS, rather than recurrence risk levels. Thus, a substantial proportion of stroke survivors with a high recurrence risk transitioned to home care. These findings highlight the need to revise current medical and social welfare services and to develop targeted strategies for stroke recurrence prevention, based on a more detailed understanding of the living environments of stroke survivors.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"14 ","pages":"20480040251362577"},"PeriodicalIF":1.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}